Ozempic vs Liraglutide: Real-World Evidence Comparison
Semaglutide generally produced greater average weight loss in the studies below, but the product, dose and study population matter. For diabetes-dose injections, the relevant direct trial is SUSTAIN 10. For obesity-dose injections, it is STEP 8. A real-world cohort supplies a different kind of evidence: what happened in routine care, where medication access and persistence varied. [1-3]
Ozempic contains semaglutide. Liraglutide is a different medicine, used in products with their own indications and dosing. Generic liraglutide is not generic Ozempic. Neither a trial average nor a lower pharmacy quote determines which prescription is appropriate for an individual.
Three comparisons that answer different questions
| Study | Population and treatment | Main result | Important limit |
|---|---|---|---|
| SUSTAIN 10, randomized, open label [1] | 577 adults with type 2 diabetes; semaglutide 1.0 mg weekly versus liraglutide 1.2 mg daily for 30 weeks | Mean A1c fell 1.7 versus 1.0 percentage points; weight fell 5.8 versus 1.9 kg | This was not a comparison against liraglutide 1.8 mg or obesity-dose liraglutide. |
| STEP 8, randomized, open label [2] | Adults with overweight or obesity without diabetes; semaglutide 2.4 mg weekly versus liraglutide 3.0 mg daily, alongside diet and activity counseling | Mean weight change at 68 weeks was -15.8% versus -6.4% | These are obesity-treatment doses, not a direct estimate of what Ozempic will do. |
| Gasoyan and colleagues, retrospective cohort [3] | 3,389 adults with obesity using injectable semaglutide or liraglutide for diabetes or obesity | Average one-year weight change was -5.1% versus -2.2% | Treatment was not randomly assigned; dose, indication and persistence differed. |
The values in each row belong to that study. Combining them into a single “expected weight loss” number would obscure important differences in who was treated and how treatment was delivered.
What SUSTAIN 10 tells us about diabetes treatment
SUSTAIN 10 compared semaglutide 1.0 mg with liraglutide 1.2 mg, added to one to three oral diabetes medicines. The estimated between-group differences favored semaglutide by 0.69 A1c percentage points and 3.83 kg. Gastrointestinal disorders were reported in 43.9% versus 38.3%; adverse events led to premature discontinuation in 11.4% versus 6.6%. [1]
At the doses tested, semaglutide produced greater average A1c and weight reductions, alongside more gastrointestinal adverse events and treatment discontinuations. Treatment selection should account for those benefits, tolerability and the patient's current response.
Why real-world weight loss can be smaller
The cohort study included prescriptions for both diabetes and obesity. Higher doses, an obesity-treatment indication and more persistent medication coverage were associated with greater weight reduction. A prescription record also cannot fully capture what a person actually took or all the reasons treatment changed. [3]
For a patient, that makes continuity a useful question: can the chosen treatment be obtained, tolerated and afforded over time? A higher-efficacy medicine that repeatedly becomes unavailable may not deliver the result seen in a controlled trial. Discuss refill reliability and a dosing schedule you can maintain.
Do not interpret an observational association as proof that the drug alone caused the entire difference. People prescribed the two medicines can differ in ways statistical adjustment does not fully remove.
Obesity treatment has its own direct comparison
STEP 8 directly compared injectable semaglutide 2.4 mg and liraglutide 3.0 mg. Its 9.4 percentage-point average weight-loss difference favored semaglutide. Gastrointestinal events were common in both active groups. The study's treatment schedules and rules for patients unable to tolerate the target dose differed, which also matters when interpreting discontinuation. [2]
If your main goal is weight management, discuss the specific product licensed for that purpose and your eligibility. Do not assume an Ozempic prescription, a liraglutide diabetes product and an obesity product are interchangeable simply because the active ingredients appear in a weight-loss study.
Heart and kidney outcomes require their own evidence
Liraglutide's LEADER trial compared liraglutide with placebo in people with type 2 diabetes at high cardiovascular risk. Major cardiovascular events occurred in 13.0% versus 14.9% over a median 3.8 years. That is an absolute difference of 1.9 percentage points in that trial, not a comparison with semaglutide. [4]
Semaglutide's SUSTAIN 6 trial also evaluated cardiovascular outcomes against placebo. Comparing its result with LEADER does not establish which drug is better for cardiovascular protection, because the populations, treatment periods and trial designs differ. [5]
Current Ozempic labeling includes cardiovascular risk reduction for adults with type 2 diabetes and established cardiovascular disease, and kidney-related risk reduction for adults with type 2 diabetes and chronic kidney disease. A clinician should match an indication to the person's actual diagnosis rather than select treatment from weight-loss results alone. [6]
Cost: compare the exact prescription
The FDA approved the first generic referencing Victoza in December 2024. That approval does not make every liraglutide product the same prescription or establish an individual's pharmacy price. [8]
Ask the pharmacy for the product, strength, quantity, days supplied and final patient charge. Ask the insurer whether the intended diagnosis is covered and whether authorization is required. Record any renewal conditions or discount eligibility. An inexpensive first fill is not enough to estimate a year's cost.
A decision framework for your appointment
| Your priority | Information to bring | Decision to discuss |
|---|---|---|
| Better glucose control | Recent A1c, glucose readings and current medicines | Whether the current regimen needs adjustment |
| Weight management | Weight history, treatment goals and prior response | Which product and indication fit the clinical situation |
| Heart or kidney protection | Cardiovascular diagnoses and kidney results | Which outcome evidence and labeled indication apply |
| Fewer treatment interruptions | Refill history, side effects and coverage notices | A plan that can be sustained |
| Lower out-of-pocket cost | Written quotes for the actual prescriptions | Total ongoing cost and covered alternatives |
Safety and switching
Both Ozempic and Victoza have a boxed thyroid C-cell tumor warning and contraindications involving a personal or family history of medullary thyroid carcinoma or MEN2. A generic reference to “thyroid disease” is not specific enough to determine eligibility. Review the exact diagnosis with the prescriber. [6,7]
Severe persistent abdominal pain, serious allergic symptoms or vomiting that prevents hydration need prompt medical assessment. Discuss other diabetes medicines, pregnancy plans, gastrointestinal problems and planned anesthesia with the prescribing team. Ozempic labeling also calls for attention to diabetic retinopathy. [6,7]
There is no milligram-for-milligram conversion between these medicines. The prescriber should specify the last dose of the old treatment, first dose of the new one and follow-up plan. Do not overlap them or copy another person's schedule.
Frequently asked questions
Frequently asked questions
Is liraglutide generic Ozempic?
Does semaglutide always cause more weight loss?
Can I compare STEP 8 directly with my Ozempic prescription?
Should I switch if liraglutide is working?
References
- Capehorn MS, et al. SUSTAIN 10: semaglutide 1.0 mg versus liraglutide 1.2 mg. Diabetes & Metabolism. 2020;46:100-109. DOI: 10.1016/j.diabet.2019.101117.
- Rubino DM, et al. STEP 8 randomized clinical trial. JAMA. 2022;327:138-150. DOI: 10.1001/jama.2021.23619.
- Gasoyan H, et al. One-Year Weight Reduction With Semaglutide or Liraglutide in Clinical Practice. JAMA Network Open. 2024;7:e2433326. DOI: 10.1001/jamanetworkopen.2024.33326.
- Marso SP, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. New England Journal of Medicine. 2016;375:311-322. DOI: 10.1056/NEJMoa1603827.
- Marso SP, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine. 2016;375:1834-1844. DOI: 10.1056/NEJMoa1607141.
- Novo Nordisk. Ozempic prescribing information. Accessed September 29, 2026.
- Novo Nordisk. Victoza prescribing information. Accessed September 29, 2026.
- FDA. First generic referencing Victoza approved. December 23, 2024.